Can avatrombopag be taken for a long time?

Avatrombopag, sold under the trade name Sucoxin, is a thrombopoietin receptor agonist. It is mainly used to treat adult patients with thrombocytopenia associated with chronic liver disease, especially before elective invasive examinations or surgeries, to increase platelet counts to reduce the risk of bleeding. However, this drug is not suitable for long-term treatment.

Long-term use of avatrombopag may cause a series of adverse effects. According to clinical studies and patient feedback, common adverse reactions include fever, abdominal pain, nausea, headache, fatigue and peripheral edema. More seriously, avatrombopag may be associated with thrombosis and thromboembolic complications in patients with chronic liver disease. These risks make long-term use of avatrombopag unsafe.

In addition to adverse effects, there are strict restrictions on the use of avatrombopag. In general, avatrombopag should only be taken orally for a maximum of 5 days because its platelet-elevating effects are dose- and exposure-dependent. The platelet count began to increase within 3 to 5 days after administration, reached a peak on 10 to 13 days, and then gradually decreased. Therefore, long-term use does not bring sustained improvement in efficacy, but may increase the risk of adverse reactions.

In special populations, such as pregnant and breastfeeding women, use of avatrombopag may cause harm to the fetus or infant. Therefore, you should consult your doctor and carefully assess the risks before use. In addition, children are not recommended to use this drug, and elderly patients should also use it under the guidance of a doctor and pay close attention to possible side effects.